Botulinum Neurotoxin Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions containing botulinum toxin face stability issues due to the use of mammalian-derived proteins like albumin and gelatin, which can transmit pathogens and require regulatory scrutiny, and existing formulations of botulinum toxin complexes are prone to potency loss during storage and handling.
Innovation Solution
Development of pharmaceutical compositions comprising botulinum neurotoxin free of complexing proteins, stabilized with non-proteinaceous agents such as hyaluronic acid, polyvinylpyrrolidone, or polyethyleneglycol, and formulated to maintain biological activity and stability, including the use of sodium acetate as a pH buffer and polyalcohols like inositol or mannitol as cryoprotectants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If mammalian-derived proteins (albumin, gelatin) are used as stabilizers in botulinum toxin formulations, then protein stability is improved, but pathogen transmission risk and immunogenicity increase
Solution Approach 1:
The patent removes mammalian-derived proteins (albumin, gelatin) from the formulation entirely, extracting the harmful stabilizing agents while maintaining stability through alternative non-proteinaceous means such as sugars, polyols, and amino acids
Solution Approach 2:
The patent replaces expensive, risky mammalian proteins with safer, synthetic or plant-derived stabilizers that are non-immunogenic and free from pathogen transmission risks
2Ease of operation
If botulinum toxin complexes are stored after reconstitution, then ease of use is improved, but potency stability deteriorates
Solution Approach 1:
The patent incorporates stabilizers into the formulation before storage, preparing the toxin in advance with protective agents that prevent degradation during storage and handling, thereby maintaining potency without requiring immediate use
Solution Approach 2:
The patent adds stabilizing agents (sugars, polyols, amino acids) that act as cushioning agents, protecting the botulinum toxin from denaturation and degradation during storage, freeze-drying, and reconstitution processes
3Stability of the object's composition
If freeze-drying is used to stabilize botulinum toxin, then storage stability is improved, but toxin activity may be reduced due to detoxification conditions
Solution Approach 1:
The patent introduces stabilizing agents (sugars, polyols, amino acids) as intermediary substances that protect the toxin during freeze-drying, mediating between the harsh drying conditions and the sensitive toxin to preserve its activity while achieving storage stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions exhibit enhanced stability and reduced immunogenicity, maintaining potency for extended periods without significant loss, even when freeze-dried, and are effective for various therapeutic and cosmetic applications.
Implementation Method 1
a non-proteinaceous stabilizing agent which retains the biological activity of the botulinum neurotoxin in an aqueous solution
Implementation Method 2
the use of sodium acetate as a pH buffer
Implementation Method 3
polyalcohols like inositol or mannitol as cryoprotectants
Implementation Method 4
even when freeze-dried
Data Source
AI summary
The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.